"Lupin partners Eli Lilly to market diabetes drug 'Eglucent' "
Lupin | December 01, 2016
Pharma major LupinBSE 1.39 % today announced a new partnership with Eli Lilly India to market and sell the latter's diabetes treatment drug 'Eglucent' in the country. "According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import," Lupin said in a BSE filing